Imigran (Sumatriptan)

Sumatriptan acts as an agonist at serotonin 5‑HT1B and 5‑HT1D receptors located on intracranial blood vessels and trigeminal nerve fibers. By stimulating these receptors, it causes vasoconstriction of dilated cranial arteries and blocks the release of inflammatory neuropeptides, interrupting the migraine cascade.

The prescribed dose of Imigran is determined by a qualified healthcare professional based on the individual’s clinical condition, severity of migraine, and prior response to therapy. Patients should follow the prescriber’s instructions and not exceed the recommended number of doses within a 24‑hour period.

Safety data for sumatriptan in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician.

To place an order, submit an enquiry on the Imigran product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imigran (sumatriptan nasal spray) belongs to the triptan class, which is generally more specific for migraine than non‑specific analgesics such as NSAIDs. Compared with oral triptans, the nasal spray offers faster absorption and may be preferable for patients with nausea or vomiting during attacks.

Imigran should be stored at room temperature, below 25 °C. Keep the nasal spray in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is securely closed to maintain product integrity.

Imigran is administered as a single spray into each nostril, as directed by the prescriber. The patient should tilt the head slightly forward, insert the nozzle, and press the actuator to deliver the dose. No water or food is required before or after administration.

The most serious risks include chest pain or tightness indicating possible coronary vasospasm, severe allergic reactions such as anaphylaxis, and serotonin syndrome when combined with other serotonergic agents. Patients experiencing any of these symptoms should seek immediate medical attention.

Imigran is contraindicated in patients with a history of coronary artery disease, uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to sumatriptan or any component of the formulation. It should also be avoided in individuals taking MAO inhibitors or ergot alkaloids.